Michael Hallek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5948919/publications.pdf

Version: 2024-02-01

349 papers	16,980 citations	24978 57 h-index	18606 119 g-index
366 all docs	366 docs citations	366 times ranked	17579 citing authors

#	Article	IF	Citations
1	Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapy. Supportive Care in Cancer, 2022, 30, 167-176.	1.0	16
2	Supervised pelvic floor muscle exercise is more effective than unsupervised pelvic floor muscle exercise at improving urinary incontinence in prostate cancer patients following radical prostatectomy â€“ a systematic review and meta-analysis. Disability and Rehabilitation, 2022, 44, 5374-5385.	0.9	18
3	Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. Haematologica, 2022, 107, 187-200.	1.7	10
4	The CLL12 trial: ibrutinib vs placebo in treatment-naÃ¯ve, early-stage chronic lymphocytic leukemia. Blood, 2022, 139, 177-187.	0.6	40
5	Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomesâ€”results of a retrospective analysis from a German university hospital. Annals of Hematology, 2022, 101, 389-395.	0.8	13
6	Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. European Journal of Haematology, 2022, 108, 369-378.	1.1	5
7	Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients. Biomarker Insights, 2022, 17, 117727192110679.	1.0	2
8	KIR2DS1â€“HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematology,the, 2022, 9, e133-e142.	2.2	5
9	Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis. Intensive Care Medicine, 2022, 48, 332-342.	3.9	25
10	Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. Infection, 2022, , 1.	2.3	0
11	Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection, 2022, 50, 1399-1404.	2.3	20
12	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere, 2022, 6, e692.	1.2	6
13	Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 2022, 139, 1318-1329.	0.6	30
14	A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem, 2022, 3, 492-506.	0.4	2
15	SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia, 2022, 36, 562-565.	3.3	23
16	Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. Frontiers in Bioengineering and Biotechnology, 2022, 10, 867042.	2.0	8
17	Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany. BMC Health Services Research, 2022, 22, 543.	0.9	12
18	The role of minimal residual disease in chronic lymphocytic leukemia.. Clinical Advances in Hematology and Oncology, 2022, 20, 97-103.	0.3	0

#	Article	IF	Citations
19	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. Leukemia, 2022, 36, 1794-1805.	3.3	1
20	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere, 2022, 6, e729.	1.2	3
21	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 2022, 36, 2125-2128.	3.3	4
22	Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARSâ€CoVâ€2 mRNA vaccination. EMBO Molecular Medicine, 2022, 14, .	3.3	7
23	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica, 2021, 106, 543-554.	1.7	12
24	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	0.6	72
25	Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplantation, 2021, 56, 716-719.	1.3	20
26	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 223-234.	5.1	93
27	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. Haematologica, 2021, , .	1.7	2
28	MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood, 2021, 138, 544-556.	0.6	14
29	Impact of induction chemotherapy on objective and self-perceived cognitive performance in patients suffering from hematological disorders. Leukemia and Lymphoma, 2021, 62, 1-5.	0.6	0
30	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2021, 137, 2267-2271.	0.6	10
31	Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discovery, 2021, 11, 2266-2281.	7.7	42
32	First manifestation of adult-onset Still's disease after COVID-19. Lancet Rheumatology, The, 2021, 3, e319-e321.	2.2	36
33	What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?. Annals of Hematology, 2021, 100, 1377-1389.	0.8	4
34	Longâ€lived macrophage reprogramming drives spike proteinâ€mediated inflammasome activation in COVIDâ€19. EMBO Molecular Medicine, 2021, 13, e14150.	3.3	98
35	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer, 2021, 21, 719.	1.1	10
36	Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 2021, 138, 1805-1816.	0.6	7

#	Article	IF	Citations
37	Healthâ€related quality of life with fixedâ€duration venetoclaxâ€obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 <scp>CLL14</scp> trial. American Journal of Hematology, 2021, 96, 1112-1119.	2.0	5
38	CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. Frontiers in Cell and Developmental Biology, 2021, 9, 698503.	1.8	4
39	Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Regional Health - Europe, The, 2021, 6, 100122.	3.0	452
40	Providing care in isolation while awaiting SARS-CoV-2 test results. Medicine (United States), 2021, 100, e26720.	0.4	0
41	Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications. International Journal of Molecular Sciences, 2021, 22, 9211.	1.8	13
42	Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients. International Journal of Molecular Sciences, 2021, 22, 9337.	1.8	4
43	Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. American Journal of Hematology, 2021, 96, E457-E460.	2.0	3
44	Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. European Journal of Cancer, 2021, 155, 281-290.	1.3	4
45	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	5.8	15
46	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. American Journal of Hematology, 2021, 96, 1679-1705.	2.0	150
47	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of Clinical Oncology, 2021, 39, 4049-4060.	0.8	74
48	Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer Journal, 2021, 11, 174.	2.8	11
49	Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. Blood, 2021, 138, 1552-1552.	0.6	1
50	A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma. Blood, 2021, 138, 712-712.	0.6	1
51	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 2639-2639.	0.6	1
52	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 72-72.	0.6	3
53	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood, 2021, 138, 2634-2634.	0.6	4
54	Obinutuzumab in Allogeneic Transplantation for CLL and Richterâ€™s Transformation in the Age of Targeted Therapies. HemaSphere, 2021, 5, e664.	1.2	0

#	Article	IF	Citations
55	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 2021, 138, 71-71.	0.6	36
56	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica, 2021, 106, 2834-2844.	1.7	3
57	The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia, 2020, 34, 296-300.	3.3	23
58	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica, 2020, 105, 1379-1390.	1.7	24
59	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 2020, 34, 1177-1181.	3.3	6
60	Bridging antifungal prophylaxis with 50Âmg or 100Âmg micafungin in allogeneic stem cell transplantation: A retrospective analysis. European Journal of Haematology, 2020, 104, 291-298.	1.1	6
61	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. International Journal of Molecular Sciences, 2020, 21, 7211.	1.8	17
62	CD74 is dispensable for development of chronic lymphocytic leukemia in EÂμ-TCL1 transgenic mice. Leukemia and Lymphoma, 2020, 61, 2799-2810.	0.6	3
63	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2020, 2020, 357-362.	0.9	22
64	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2020, 61, 3188-3197.	0.6	26
65	Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the EÂμ-TCL1 Transgenic Mouse Model. Cancers, 2020, 12, 1980.	1.7	6
66	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics, 2020, 22, 1300-1307.	1.2	9
67	Evaluation of a complex integrated, cross-sectoral psycho-oncological care program (isPO): a mixed-methods study protocol. BMJ Open, 2020, 10, e034141.	0.8	20
68	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1188-1200.	5.1	208
69	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARSâ€CoVâ€2ÂPandemic. HemaSphere, 2020, 4, e432.	1.2	18
70	Relevant Cytokines in the B Cell Lymphoma Micro-Environment. Cancers, 2020, 12, 2525.	1.7	6
71	Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2. Cancers, 2020, 12, 2303.	1.7	9
72	The proteomic landscape of small urinary extracellular vesicles during kidney transplantation. Journal of Extracellular Vesicles, 2020, 10, e12026.	5.5	30

#	Article	IF	Citations
73	Economic Impact of the Introduction of Outpatient Medical Specialist Care (ASV) of Gastrointestinal Cancer Patients from a German Hospital Management Perspective. Oncology Research and Treatment, 2020, 43, 498-505.	0.8	2
74	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 2020, 135, 2402-2412.	0.6	83
75	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	0.6	86
76	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. Haematologica, 2020, 105, e519.	1.7	8
77	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 2020, 34, 2225-2229.	3.3	39
78	COVIDâ€19 complicated by parainfluenza coâ€infection in a patient with chronic lymphocytic leukemia. European Journal of Haematology, 2020, 105, 508-511.	1.1	10
79	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica, 2020, 105, 2598-2607.	1.7	44
80	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 2020, 34, 2038-2050.	3.3	38
81	Long Term Followâ€up Data and Healthâ€Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). HemaSphere, 2020, 4, e336.	1.2	31
82	Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia, 2020, 34, 1038-1051.	3.3	24
83	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nature Communications, 2020, 11, 363.	5.8	75
84	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Reports, 2020, 31, 107568.	2.9	15
85	Invasive Aspergillosis in Patients Treated With Ibrutinib. HemaSphere, 2020, 4, e309.	1.2	9
86	Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma. Frontiers in Immunology, 2020, 11, 398.	2.2	10
87	COVIDâ€19 associated pulmonary aspergillosis. Mycoses, 2020, 63, 528-534.	1.8	434
88	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 2020, 135, 866-870.	0.6	30
89	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. Eurosurveillance, 2020, 25, .	3.9	18
90	Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in EÂµ-TCL1 mice. Blood Advances, 2020, 4, 6106-6116.	2.5	8

#	Article	IF	Citations
91	Cell lineâ€based assessment of BTK inhibitors. British Journal of Pharmacology, 2020, 177, 2163-2165.	2.7	0
92	The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression. Blood, 2020, 136, 2-2.	0.6	0
93	BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE. Neuro-Oncology, 2020, 22, ii10-ii10.	0.6	0
94	Robust Discovery of Candidate DNA Methylation Cancer Drivers. Blood, 2020, 136, 33-34.	0.6	0
95	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13.	0.6	0
96	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. Blood, 2020, 136, 3-4.	0.6	2
97	Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. Annals of Hematology, 2019, 98, 2605-2607.	0.8	8
98	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 715-722.e6.	0.2	35
99	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 2019, 94, 1266-1287.	2.0	352
100	FimH-based display of functional eukaryotic proteins on bacteria surfaces. Scientific Reports, 2019, 9, 8410.	1.6	3
101	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell, 2019, 178, 699-713.e19.	13.5	138
102	Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. Theranostics, 2019, 9, 6047-6062.	4.6	43
103	The economic burden of endoscopic treatment for anastomotic leaks following oncological Ivor Lewis esophagectomy. PLoS ONE, 2019, 14, e0221406.	1.1	12
104	International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S278.	0.2	1
105	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncology, The, 2019, 20, 1576-1586.	5.1	26
106	Early Palliative Care: Pro, but Please Be Precise!. Oncology Research and Treatment, 2019, 42, 11-18.	0.8	21
107	HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?. Infection, 2019, 47, 293-300.	2.3	6
108	New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia, 2019, 33, 576-587.	3.3	26

#	Article	IF	Citations
109	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2019, 94, 1002-1006.	2.0	5
110	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	13.9	599
111	How to approach CLL in clinical practice. Hematological Oncology, 2019, 37, 38-42.	0.8	15
112	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in â€œReal-Lifeâ€•Outside of Clinical Trials. Anticancer Research, 2019, 39, 2591-2598.	0.5	2
113	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2019, 37, 1391-1402.	0.8	177
114	Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update. Hematologic Malignancies, 2019, , 69-77.	0.2	0
115	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood, 2019, 134, 111-122.	0.6	145
116	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia, 2019, 33, 2183-2194.	3.3	19
117	Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Scientific Reports, 2019, 9, 3631.	1.6	57
118	Extracellular vesicle measurements with nanoparticle tracking analysis â€“ An accuracy and repeatability comparison between NanoSight NS300 and ZetaView. Journal of Extracellular Vesicles, 2019, 8, 1596016.	5.5	318
119	Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Haematologica, 2019, 104, e224-e226.	1.7	6
120	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica, 2019, 104, 1798-1803.	1.7	10
121	Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report. Integrative Cancer Therapies, 2019, 18, 153473541983235.	0.8	3
122	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica, 2019, 104, 2144-2154.	1.7	20
123	Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.). Haematologica, 2019, 104, e540-e540.	1.7	13
124	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. HemaSphere, 2019, 3, e287.	1.2	33
125	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, 488-495.	2.0	21
126	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1161-1172.	3.3	38

#	Article	IF	Citations
127	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leukemia and Lymphoma, 2019, 60, 1438-1446.	0.6	12
128	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 2019, 133, 494-497.	0.6	32
129	New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabineâ€“mitoxantroneâ€“cyclophosphamideâ€“alemtuzumab induction followed by alemtuzumab maintenance. Leukemia and Lymphoma, 2019, 60, 649-657.	0.6	15
130	Antiâ€<scp>CD</scp>20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the <scp>CLLX</scp>4 trial. British Journal of Haematology, 2019, 184, 833-836.	1.2	6
131	Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States. Blood, 2019, 134, 4741-4741.	0.6	8
132	Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group. Blood, 2019, 134, 3040-3040.	0.6	1
133	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood, 2019, 134, 36-36.	0.6	18
134	Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial. Blood, 2019, 134, 4305-4305.	0.6	2
135	Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial. Blood, 2019, 134, 4315-4315.	0.6	3
136	A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 4297-4297.	0.6	5
137	Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematology American Society of Hematology Education Program, 2019, 2019, 482-489.	0.9	2
138	The Treatment of Chronic Lymphatic Leukemia. Deutsches Ärzteblatt International, 2019, 116, 41-46.	0.6	11
139	Initial Therapy of Chronic Lymphocytic Leukemia. Hematologic Malignancies, 2019, , 79-96.	0.2	2
140	Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG). Blood, 2019, 134, 3046-3046.	0.6	2
141	Analysis of Outcomes of Younger (â‰¤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG). Blood, 2019, 134, 4293-4293.	0.6	0
142	BIM Regulation Is BTK Dependent and Can be Targeted By Entospletinib in Ibrutinib Refractory Mutants. Blood, 2019, 134, 1765-1765.	0.6	0
143	Lyn Kinase Contributes to the Reprogramming of Fibroblasts Promoting Chronic Lymphocytic Leukemia Progression. Blood, 2019, 134, 4283-4283.	0.6	0
144	Chronic lymphocytic leukaemia. Lancet, The, 2018, 391, 1524-1537.	6.3	233

#	Article	IF	Citations
145	Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nature Communications, 2018, 9, 727.	5.8	160
146	Venetoclax after idelalisib: relevant progress for CLL. Blood, 2018, 131, 1632-1633.	0.6	5
147	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplantation, 2018, 53, 255-263.	1.3	14
148	A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 2018, 131, 955-962.	0.6	61
149	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 2018, 131, 2745-2760.	0.6	1,069
150	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology, 2018, 14, 499-513.	1.1	27
151	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leukemia and Lymphoma, 2018, 59, 1614-1623.	0.6	12
152	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B - Clinical Cytometry, 2018, 94, 121-128.	0.7	133
153	NFATC1 activation by <scp>DNA</scp> hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. International Journal of Cancer, 2018, 142, 322-333.	2.3	33
154	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology, 2018, 36, 1973-1980.	0.8	257
155	On the architecture of translational research designed to control chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2018, 2018, 1-8.	0.9	10
156	Outcome of patients aged 80Âyears or older treated for chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 183, 727-735.	1.2	7
157	Management of unfit elderly patients with chronic lymphocytic leukemia. European Journal of Internal Medicine, 2018, 58, 7-13.	1.0	8
158	Der Ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis. Oncology Research and Treatment, 2018, 41, 2-26.	0.8	2
159	Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Design, Development and Therapy, 2018, Volume 12, 2577-2590.	2.0	49
160	Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene, 2018, 37, 5682-5693.	2.6	29
161	Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients. In Vivo, 2018, 32, 819-824.	0.6	16
162	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. BioMed Research International, 2018, 2018, 1-9.	0.9	20

#	Article	IF	Citations
163	Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment - A Systematic Review. Breast Care, 2018, 13, 380-385.	0.8	33
164	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 1215-1228.	5.1	94
165	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2018, 24, 4371-4379.	3.2	127
166	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 2018, 132, 694-694.	0.6	16
167	Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4430-4430.	0.6	1
168	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood, 2018, 132, 1859-1859.	0.6	1
169	DNA Damage-Response Pathway in Lymphoma Determines Interactions with Macrophages By Altered PD-L1 Expression and Exosome Formation. Blood, 2018, 132, 275-275.	0.6	0
170	Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 2018, 132, 583-583.	0.6	0
171	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 2018, 132, 4429-4429.	0.6	0
172	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 2018, 132, 1866-1866.	0.6	0
173	FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 399-407.	0.6	13
174	Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells. Haematologica, 2017, 102, e100-e103.	1.7	15
175	Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4ÂGy TBI with treosulfan in an elderly population with high-risk AML. Annals of Hematology, 2017, 96, 479-487.	0.8	12
176	On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission. Clinical Infectious Diseases, 2017, 65, 1404-1406.	2.9	6
177	Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the microâ€environmental dialogue. British Journal of Haematology, 2017, 178, 949-953.	1.2	7
178	Role and timing of new drugs in CLL. Hematological Oncology, 2017, 35, 30-32.	0.8	2
179	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	3.2	27
180	Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Therapeutic Advances in Hematology, 2017, 8, 197-205.	1.1	9

#	Article	IF	Citations
181	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017, 129, 2702-2705.	0.6	108
182	Impact of telomere length on the outcome of allogeneic stem cell transplantation for poorâ€risk chronic lymphocytic leukaemia: results from the <scp>GCLLSG CLL</scp>3X trial. British Journal of Haematology, 2017, 179, 342-346.	1.2	2
183	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2017, 176, 618-628.	1.2	36
184	Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood, 2017, 130, 2443-2444.	0.6	6
185	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology,the, 2017, 4, e475-e486.	2.2	45
186	Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood, 2017, 130, 1477-1480.	0.6	63
187	Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 2017, 92, 946-965.	2.0	229
188	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017, 8, 153.	5.8	39
189	Using Antigen-Specific B Cells to Combine Antibody and T Cellâ€“Based Cancer Immunotherapy. Cancer Immunology Research, 2017, 5, 730-743.	1.6	23
190	Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigenâ€presenting cells in skin. FASEB Journal, 2017, 31, 526-543.	0.2	21
191	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 278-284.	2.0	38
192	Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective. European Journal of Haematology, 2017, 98, 169-176.	1.1	1
193	Antigen-presenting human B cells are expanded in inflammatory conditions. Journal of Leukocyte Biology, 2017, 101, 577-587.	1.5	28
194	Regulatory B10 cells display an altered homoeostasis in acute graftâ€versusâ€host disease. European Journal of Haematology, 2017, 98, 128-133.	1.1	4
195	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 2017, 58, 1630-1639.	0.6	102
196	Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal of Haematology, 2017, 98, 254-262.	1.1	9
197	Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology American Society of Hematology Education Program, 2017, 2017, 338-345.	0.9	19
198	Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 295-304.	2.0	15

#	Article	IF	Citations
199	Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. Eurosurveillance, 2017, 22, .	3.9	28
200	Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). , 2017, , .		2
201	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica, 2016, 101, 256-262.	1.7	42
202	Immunological effects in patients with steroidâ€refractory graftâ€versusâ€host disease following treatment with basiliximab, a <scp>CD</scp>25 monoclonal antibody. European Journal of Haematology, 2016, 97, 121-127.	1.1	17
203	<scp>FLAMSA</scp> reducedâ€intensity conditioning is equally effective in <scp>AML</scp> patients with primary induction failure as well as in first or second complete remission. European Journal of Haematology, 2016, 96, 475-482.	1.1	18
204	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. European Journal of Haematology, 2016, 97, 253-260.	1.1	19
205	Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. British Journal of Ophthalmology, 2016, 101, bjophthalmol-2015-307666.	2.1	36
206	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50Âyearsâ€"a report from the EBMT acute leukemia working party. Journal of Hematology and Oncology, 2016, 9, 65.	6.9	17
207	Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology American Society of Hematology Education Program, 2016, 2016, 149-155.	0.9	30
208	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2016, 17, 768-778.	5.1	676
209	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2016, 17, 928-942.	5.1	529
210	A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells. Molecular Cancer Therapeutics, 2016, 15, 971-984.	1.9	6
211	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of Clinical Oncology, 2016, 34, 1386-1394.	0.8	276
212	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia and Lymphoma, 2016, 57, 1291-1299.	0.6	17
213	Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?. Leukemia and Lymphoma, 2016, 57, 987-990.	0.6	2
214	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 2016, 127, 208-215.	0.6	571
215	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood, 2016, 127, 2847-2855.	0.6	100
216	Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood, 2016, 128, 395-404.	0.6	112

#	Article	IF	Citations
217	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 2016, 128, 574-583.	0.6	69
218	LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia. Cancer Cell, 2016, 30, 610-622.	7.7	64
219	Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Practice and Research in Clinical Haematology, 2016, 29, 111-121.	0.7	3
220	New treatment approaches in CLL: Challenges and opportunities in the elderly. Journal of Geriatric Oncology, 2016, 7, 375-382.	0.5	15
221	Cytotoxicity of the <scp>CD</scp>37 antibody <scp>BI</scp> 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or <scp>PI</scp>3K inhibitors. British Journal of Haematology, 2016, 173, 791-794.	1.2	8
222	Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. Journal of Clinical Oncology, 2016, 34, 3758-3765.	0.8	142
223	RIG-I activation induces the release of extracellular vesicles with antitumor activity. OncoImmunology, 2016, 5, e1219827.	2.1	44
224	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 1409-1418.	5.1	290
225	Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 2016, 101, 879-883.	1.7	126
226	Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activityin vitroandin vivoagainst chronic lymphocytic leukemia. OncoImmunology, 2016, 5, e1211220.	2.1	18
227	Targeted Therapy of CLL. Oncology Research and Treatment, 2016, 39, 768-778.	0.8	9
228	Pathogenesis, Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Exciting Times. Oncology Research and Treatment, 2016, 39, 8-8.	0.8	3
229	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016, 388, 565-575.	6.3	328
230	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology, 2016, 5, e1150399.	2.1	94
231	Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	4
232	Ultrasoundâ€guided core needle biopsies for workup of lymphadenopathy and lymphoma. European Journal of Haematology, 2016, 97, 379-386.	1.1	35
233	<scp>OCTET</scp>â€<scp>CY</scp>: a phase <scp>II</scp> study to investigate the efficacy of postâ€transplant cyclophosphamide as sole graftâ€versusâ€host prophylaxis after allogeneic peripheral blood stem cell transplantation. European Journal of Haematology, 2016, 96, 27-35.	1.1	52
234	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology, The, 2016, 17, 200-211.	5.1	373

#	Article	IF	Citations
235	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. OncoImmunology, 2016, 5, e1100789.	2.1	45
236	Advances in firstâ€line treatment of chronic lymphocytic leukemia: current recommendations on management and firstâ€line treatment by the German <scp>CLL</scp> Study Group (<scp>GCLLSG</scp>). European Journal of Haematology, 2016, 96, 9-18.	1.1	28
237	State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. Oncology Research and Treatment, 2016, 39, 25-32.	0.8	27
238	Initial therapy of chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 241-250.	0.8	11
239	Physical exercise modulates the homeostasis of human regulatory T cells. Journal of Allergy and Clinical Immunology, 2016, 137, 1607-1610.e8.	1.5	65
240	Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2016, 57, 1130-1139.	0.6	12
241	Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leukemia and Lymphoma, 2016, 57, 789-796.	0.6	87
242	Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Leukemia and Lymphoma, 2016, 57, 596-603.	0.6	4
243	Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. Blood, 2016, 128, 192-192.	0.6	11
244	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 2016, 128, 2042-2042.	0.6	9
245	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 2044-2044.	0.6	4
246	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 2016, 128, 2054-2054.	0.6	8
247	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 2016, 128, 229-229.	0.6	12
248	ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 3197-3197.	0.6	4
249	Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. Blood, 2016, 128, 3227-3227.	0.6	19
250	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3230-3230.	0.6	12
251	Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL. Blood, 2016, 128, 354-354.	0.6	1
252	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. Blood, 2016, 128, 3705-3705.	0.6	23

#	Article	IF	Citations
253	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	0.6	1
254	Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 2016, 128, 4382-4382.	0.6	11
255	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4393-4393.	0.6	17
256	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4395-4395.	0.6	7
257	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population. Blood, 2016, 128, 4401-4401.	0.6	9
258	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 2016, 128, 640-640.	0.6	9
259	Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. Blood, 2016, 128, 682-682.	0.6	3
260	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS ONE, 2016, 11, e0160871.	1.1	12
261	CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro. Oncotarget, 2016, 7, 30523-30535.	0.8	43
262	Transformation of Chronic Lymphocytic Leukemia Towards RichterÂ´s Syndrome Is Induced By AKT Activation. Blood, 2016, 128, 2031-2031.	0.6	0
263	APT1-Mediated Cross-Talk Between Palmitoylation and Phosphorylation Events of the BCR Pathway Sensitizes CLL Cells Towards BCR-Associated Kinase Inhibitors. Blood, 2016, 128, 4361-4361.	0.6	1
264	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 4394-4394.	0.6	1
265	Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis. Blood, 2016, 128, 5588-5588.	0.6	0
266	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2016, 128, 3504-3504.	0.6	0
267	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood, 2015, 126, 2646-2649.	0.6	64
268	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	13.7	1,634
269	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 2015, 90, 446-460.	2.0	212
270	Towards improved frontline treatment of CLL in the elderly. Lancet, The, 2015, 385, 1814-1815.	6.3	2

#	Article	IF	Citations
271	The HELIOS trial protocol: a PhaseÂIII study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncology, 2015, 11, 51-59.	1.1	22
272	Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Molecular Cancer, 2015, 14, 114.	7.9	23
273	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncology, 2015, 11, 1895-1903.	1.1	34
274	Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica, 2015, 100, 1451-1459.	1.7	34
275	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. Blood, 2015, 126, LBA-6-LBA-6.	0.6	13
276	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT. Blood, 2015, 126, 3105-3105.	0.6	0
277	Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget, 2014, 5, 4651-4664.	0.8	98
278	Management of chronic lymphocytic leukemia. Haematologica, 2014, 99, 965-972.	1.7	38
279	Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual. Leukemia Research, 2014, 38, 284-285.	0.4	1
280	Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia. Seminars in Hematology, 2014, 51, 235-248.	1.8	8
281	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 2014, 124, 49-62.	0.6	244
282	Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy. Cell, 2014, 156, 590-602.	13.5	155
283	Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer. Trends in Molecular Medicine, 2014, 20, 72-82.	3.5	20
284	Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy. Molecular Therapy, 2014, 22, 929-939.	3.7	41
285	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica, 2014, 99, 1095-1100.	1.7	101
286	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood, 2014, 124, 420-425.	0.6	14
287	Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood, 2014, 124, 2196-2202.	0.6	138
288	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 2013, 88, 803-816.	2.0	143

#	Article	IF	Citations
289	Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology American Society of Hematology Education Program, 2013, 2013, 138-150.	0.9	33
290	Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood, 2013, 122, 3723-3734.	0.6	99
291	TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). Blood, 2013, 122, 1638-1638.	0.6	3
292	Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT. Blood, 2013, 122, 545-545.	0.6	3
293	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. Journal of Clinical Oncology, 2013, 31, 7004-7004.	0.8	20
294	Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (<scp>CLL</scp>): results of a multicentre phase <scp>II</scp> study of the German <scp>CLL</scp> Study Group (<scp>GCLLSG</scp>). British Journal of Haematology, 2012, 158, 238-241.	1.2	8
295	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood, 2012, 120, 151-151.	0.6	52
296	Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	20
297	Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. Blood, 2012, 120, 433-433.	0.6	7
298	NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg. Blood, 2012, 120, 710-710.	0.6	1
299	Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. Blood, 2012, 120, 2874-2874.	0.6	0
300	Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG). Blood, 2011, 118, 2863-2863.	0.6	2
301	B Cell Receptor Stimulation of CLL Cells Leads to Upregulation of IRF4 Proteinexpression Influenced by SNP Expression,. Blood, 2011, 118, 3886-3886.	0.6	0
302	B-Cell Receptor-Mediated Glucosylceramide Synthesis Protects Primary CLL Cells From Ceramide-Dependent Apoptosis. Blood, 2011, 118, 1766-1766.	0.6	3
303	Therapy of chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2010, 23, 85-96.	0.7	26
304	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	27
305	Novel X-Linked Inhibitor of Apoptosis (XIAP) Inhibiting Compound as Sensitizer for TRAIL-Mediated Apoptosis In Chronic Lymphocytic Leukemia with Poor Prognosis. Blood, 2010, 116, 1375-1375.	0.6	2
306	Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. Blood, 2010, 116, 2357-2357.	0.6	3

#	Article	IF	Citations
307	Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG. Blood, 2010, 116, 2427-2427.	0.6	11
308	High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia. Blood, 2010, 116, 50-50.	0.6	1
309	Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine â€“ Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. Blood, 2010, 116, 920-920.	0.6	16
310	IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG). Blood, 2010, 116, 3609-3609.	0.6	0
311	Microenvironment Influences Expression of TOSO â€“ a Novel NF-Kappa B Target Gene In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 695-695.	0.6	0
312	High Lymphoid Enhancer-Binding Factor-1 (LEF1) Expression Is Associated with ZAP70 Positivity, Requirement of Treatment, and Fibromodulin (FMOD) Expression In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 1715-1715.	0.6	3
313	Acute Myeloid Leukemia and Survival on the Intensive Care Unit (ICU) - Biology- and Treatment-Related Determinants of Outcome - An Analysis of the AML-CG. Blood, 2010, 116, 2166-2166.	0.6	0
314	TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.. Blood, 2009, 114, 1267-1267.	0.6	9
315	Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 2373-2373.	0.6	2
316	Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 3438-3438.	0.6	2
317	First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.. Blood, 2009, 114, 535-535.	0.6	142
318	Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.. Blood, 2009, 114, 877-877.	0.6	2
319	Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.. Blood, 2009, 114, 879-879.	0.6	2
320	Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.. Blood, 2009, 114, 880-880.	0.6	27
321	Deregulation of miRNAs by Epigenetic Silencing Disrupts Suppression of the Oncogene PLAG1 in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 3463-3463.	0.6	0
322	Vascular Endothelial Growth Factor (VEGF) Acts Via Auto- and Paracrine Mechanisms as a Critical Microenvironmental Factor for the Survival of Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2009, 114, 4376-4376.	0.6	0
323	Potent Antineoplastic Activity of Two Inhibitors of Lymphoid Enhancer Binding Factor-1 (LEF-1) in Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2009, 114, 885-885.	0.6	0
324	Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience.. Blood, 2009, 114, 2293-2293.	0.6	0

#	Article	IF	Citations
325	Long-Term Follow-up of Rituximab Treatment of Non-Familial Idiopathic Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2009, 114, 3513-3513.	0.6	12
326	The Para-Isomer of Nitric Oxide Donating Acetylsalicylic Acid (p-NO-ASA) Induces Apoptosis in Chronic Lymphocytic Leukemia (CLL) in Vitro and In Vivo without Gross Systemic Toxicities.. Blood, 2009, 114, 3783-3783.	0.6	4
327	New menus for CLL treatment. Oncology, 2009, 23, 1046, 1051, 1056.	0.4	0
328	Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy â€“ a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial. Blood, 2008, 112, 3139-3139.	0.6	1
329	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 325-325.	0.6	99
330	Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab â€“ a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial. Blood, 2008, 112, 326-326.	0.6	13
331	Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). Blood, 2008, 112, 330-330.	0.6	54
332	The Para-Isomer of Nitric Oxide-Donating Acetylic Salicylic Acid (p-NO-ASA) Effectively Induces Cell Death in B-Cell Chronic Lymphocytic Leukemia (CLL) Cells at Low Micromolar Concentrations.. Blood, 2008, 112, 1606-1606.	0.6	0
333	Allogeneic Stem Cell Transplantation for Relapsed Hodgkinâ€™s Disease - a Single Centre Experience. Blood, 2008, 112, 4431-4431.	0.6	0
334	Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).. Blood, 2007, 110, 2038-2038.	0.6	6
335	Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).. Blood, 2007, 110, 625-625.	0.6	13
336	No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).. Blood, 2007, 110, 629-629.	0.6	18
337	Physiologic evaluation in the elderly prior to treatment with chemotherapy. Clinical Advances in Hematology and Oncology, 2007, 5, 620-1.	0.3	1
338	Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.. Blood, 2006, 108, 2730-2730.	0.6	1
339	Impact of Different Chemotherapy Regimen in Comorbid Patients with Advanced Chronic Lymphocytic Leukemia: Metaanalysis of Two Phase-III-Trials of the German CLL Study Group.. Blood, 2006, 108, 2840-2840.	0.6	5
340	Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).. Blood, 2006, 108, 482-482.	0.6	11
341	Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.. Blood, 2006, 108, 483-483.	0.6	7
342	Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2084-2084.	0.6	0

#	Article	IF	Citations
343	Chemoimmunotherapyâ€”towards real progress in the treatment of chronic lymphocytic leukemia. Nature Clinical Practice Oncology, 2005, 2, 338-339.	4.3	3
344	CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richterâ€™s Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).. Blood, 2005, 106, 2126-2126.	0.6	4
345	17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.. Blood, 2005, 106, 715-715.	0.6	41
346	Comparison of the Efficacy and Toxicity of Fludarabine (F) in First Line Therapy of Younger Versus Elderly Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Meta-Analysis of Two Phase III Trials of the German CLL Study Group (GCLLSG).. Blood, 2005, 106, 717-717.	0.6	14
347	Fibromodulin as a Novel Tumor-Associated Antigen (TAA) in Chronic Lymphocytic Leukemia (CLL) Which Allows Expansion of Specific CD8+ Autologous T Lymphocytes.. Blood, 2004, 104, 175-175.	0.6	5
348	PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.. Blood, 2004, 104, 4662-4662.	0.6	0
349	Pharmacokinetics and Exposure-Response Analysis of Venetoclaxâ€‰+â€‰Obinutuzumab in Chronic Lymphocytic Leukemia: PhaseÂ1b Study and PhaseÂ3 CLL14 Trial. Advances in Therapy, 0, , .	1.3	0